Do analysts prefer CARM or VINC?

Carisma Therapeutics currently has a consensus target price of $1.00, indicating a potential upside of 22,122.22%. Given Carisma Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Carisma Therapeutics is more favorable than Vincerx Pharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Carisma Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Vincerx Pharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has preferable earnings & valuation, AMPE or VINC?

Ampio Pharmaceuticals is trading at a lower price-to-earnings ratio than Vincerx Pharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Ampio Pharmaceuticals N/A N/A -$8.63M -$11.01 N/A Vincerx Pharma N/A N/A -$40.16M -$5.31 N/A

Is AMPE or VINC more profitable?

Ampio Pharmaceuticals' return on equity of 0.00% beat Vincerx Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Ampio Pharmaceuticals N/A N/A N/A Vincerx Pharma N/A -248.33% -132.73%

Do analysts prefer VINC or MEHA?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Vincerx Pharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Functional Brands 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is VINC or MEHA more profitable?

Functional Brands' return on equity of 0.00% beat Vincerx Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Vincerx Pharma N/A -248.33% -132.73% Functional Brands N/A N/A N/A

Is VINC or PTPI more profitable?

Petros Pharmaceuticals' return on equity of -78.22% beat Vincerx Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Vincerx Pharma N/A -248.33% -132.73% Petros Pharmaceuticals N/A -78.22% -23.50%

Is VINC or ORGS more profitable?

Vincerx Pharma has a net margin of 0.00% compared to Orgenesis' net margin of -3,827.81%. Orgenesis' return on equity of 0.00% beat Vincerx Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Vincerx Pharma N/A -248.33% -132.73% Orgenesis -3,827.81% N/A -130.18%

Vincerx Pharma (VINC) Competitors

$0.01 0.00 (-15.89%)

As of 07/22/2026 03:37 PM Eastern

Compare

VINC vs. CARM, AMPE, MEHA, PTPI, and ORGS

Should you buy Vincerx Pharma stock or one of its competitors? MarketBeat compares Vincerx Pharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Vincerx Pharma include Carisma Therapeutics (CARM), Ampio Pharmaceuticals (AMPE), Functional Brands (MEHA), Petros Pharmaceuticals (PTPI), and Orgenesis (ORGS). These companies are all part of the "pharmaceutical products" industry.

How does Vincerx Pharma compare to Carisma Therapeutics?

Carisma Therapeutics (NASDAQ:CARM) and Vincerx Pharma (NASDAQ:VINC) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, media sentiment, risk, valuation, profitability, earnings, analyst recommendations and institutional ownership.

In the previous week, Vincerx Pharma had 1 more articles in the media than Carisma Therapeutics. MarketBeat recorded 1 mentions for Vincerx Pharma and 0 mentions for Carisma Therapeutics. Carisma Therapeutics' average media sentiment score of 0.00 equaled Vincerx Pharma'saverage media sentiment score.

Company	Overall Sentiment
Carisma Therapeutics	Neutral
Vincerx Pharma	Neutral

Carisma Therapeutics currently has a consensus target price of $1.00, indicating a potential upside of 22,122.22%. Given Carisma Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Carisma Therapeutics is more favorable than Vincerx Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Carisma Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Vincerx Pharma	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Vincerx Pharma has a net margin of 0.00% compared to Carisma Therapeutics' net margin of -254.28%. Carisma Therapeutics' return on equity of 0.00% beat Vincerx Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Carisma Therapeutics	-254.28%	N/A	-192.17%
Vincerx Pharma	N/A	-248.33%	-132.73%

44.3% of Carisma Therapeutics shares are owned by institutional investors. Comparatively, 44.0% of Vincerx Pharma shares are owned by institutional investors. 6.9% of Carisma Therapeutics shares are owned by company insiders. Comparatively, 15.6% of Vincerx Pharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Carisma Therapeutics has a beta of -9.34, indicating that its stock price is 1,034% less volatile than the broader market. Comparatively, Vincerx Pharma has a beta of 1.45, indicating that its stock price is 45% more volatile than the broader market.

Vincerx Pharma has lower revenue, but higher earnings than Carisma Therapeutics. Vincerx Pharma is trading at a lower price-to-earnings ratio than Carisma Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Carisma Therapeutics	$10.77M	0.02	-$60.48M	$0.73	0.01
Vincerx Pharma	N/A	N/A	-$40.16M	-$5.31	N/A

Summary

Carisma Therapeutics beats Vincerx Pharma on 8 of the 14 factors compared between the two stocks.

How does Vincerx Pharma compare to Ampio Pharmaceuticals?

Ampio Pharmaceuticals (NYSE:AMPE) and Vincerx Pharma (NASDAQ:VINC) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, dividends, risk, institutional ownership, valuation, analyst recommendations, earnings and media sentiment.

Ampio Pharmaceuticals has a beta of 5.96, suggesting that its stock price is 496% more volatile than the broader market. Comparatively, Vincerx Pharma has a beta of 1.45, suggesting that its stock price is 45% more volatile than the broader market.

Ampio Pharmaceuticals is trading at a lower price-to-earnings ratio than Vincerx Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ampio Pharmaceuticals	N/A	N/A	-$8.63M	-$11.01	N/A
Vincerx Pharma	N/A	N/A	-$40.16M	-$5.31	N/A

5.7% of Ampio Pharmaceuticals shares are owned by institutional investors. Comparatively, 44.0% of Vincerx Pharma shares are owned by institutional investors. 3.3% of Ampio Pharmaceuticals shares are owned by insiders. Comparatively, 15.6% of Vincerx Pharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Vincerx Pharma had 1 more articles in the media than Ampio Pharmaceuticals. MarketBeat recorded 1 mentions for Vincerx Pharma and 0 mentions for Ampio Pharmaceuticals. Ampio Pharmaceuticals' average media sentiment score of 0.00 equaled Vincerx Pharma'saverage media sentiment score.

Company	Overall Sentiment
Ampio Pharmaceuticals	Neutral
Vincerx Pharma	Neutral

Ampio Pharmaceuticals' return on equity of 0.00% beat Vincerx Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ampio Pharmaceuticals	N/A	N/A	N/A
Vincerx Pharma	N/A	-248.33%	-132.73%

Summary

Vincerx Pharma beats Ampio Pharmaceuticals on 5 of the 9 factors compared between the two stocks.

How does Vincerx Pharma compare to Functional Brands?

Vincerx Pharma (NASDAQ:VINC) and Functional Brands (NASDAQ:MEHA) are both small-cap pharmaceutical products companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, dividends, valuation, earnings, profitability, risk, institutional ownership and media sentiment.

In the previous week, Vincerx Pharma had 1 more articles in the media than Functional Brands. MarketBeat recorded 1 mentions for Vincerx Pharma and 0 mentions for Functional Brands. Vincerx Pharma's average media sentiment score of 0.00 equaled Functional Brands'average media sentiment score.

Company	Overall Sentiment
Vincerx Pharma	Neutral
Functional Brands	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vincerx Pharma	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Functional Brands	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Functional Brands has higher revenue and earnings than Vincerx Pharma. Functional Brands is trading at a lower price-to-earnings ratio than Vincerx Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vincerx Pharma	N/A	N/A	-$40.16M	-$5.31	N/A
Functional Brands	$6.67M	0.03	$760K	-$0.32	N/A

Functional Brands' return on equity of 0.00% beat Vincerx Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vincerx Pharma	N/A	-248.33%	-132.73%
Functional Brands	N/A	N/A	N/A

44.0% of Vincerx Pharma shares are owned by institutional investors. 15.6% of Vincerx Pharma shares are owned by insiders. Comparatively, 4.3% of Functional Brands shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Functional Brands beats Vincerx Pharma on 6 of the 10 factors compared between the two stocks.

How does Vincerx Pharma compare to Petros Pharmaceuticals?

Vincerx Pharma (NASDAQ:VINC) and Petros Pharmaceuticals (NASDAQ:PTPI) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, media sentiment, earnings, profitability, valuation, risk, institutional ownership and dividends.

Petros Pharmaceuticals has higher revenue and earnings than Vincerx Pharma. Petros Pharmaceuticals is trading at a lower price-to-earnings ratio than Vincerx Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vincerx Pharma	N/A	N/A	-$40.16M	-$5.31	N/A
Petros Pharmaceuticals	$5.11M	0.02	-$8.16M	-$1.64	N/A

In the previous week, Vincerx Pharma had 1 more articles in the media than Petros Pharmaceuticals. MarketBeat recorded 1 mentions for Vincerx Pharma and 0 mentions for Petros Pharmaceuticals. Vincerx Pharma's average media sentiment score of 0.00 equaled Petros Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Vincerx Pharma	Neutral
Petros Pharmaceuticals	Neutral

44.0% of Vincerx Pharma shares are held by institutional investors. Comparatively, 12.3% of Petros Pharmaceuticals shares are held by institutional investors. 15.6% of Vincerx Pharma shares are held by insiders. Comparatively, 8.2% of Petros Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Petros Pharmaceuticals' return on equity of -78.22% beat Vincerx Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vincerx Pharma	N/A	-248.33%	-132.73%
Petros Pharmaceuticals	N/A	-78.22%	-23.50%

Vincerx Pharma has a beta of 1.45, meaning that its stock price is 45% more volatile than the broader market. Comparatively, Petros Pharmaceuticals has a beta of 1.86, meaning that its stock price is 86% more volatile than the broader market.

Summary

Petros Pharmaceuticals beats Vincerx Pharma on 6 of the 10 factors compared between the two stocks.

How does Vincerx Pharma compare to Orgenesis?

Vincerx Pharma (NASDAQ:VINC) and Orgenesis (NASDAQ:ORGS) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, dividends, risk, institutional ownership, profitability, analyst recommendations, valuation and media sentiment.

44.0% of Vincerx Pharma shares are owned by institutional investors. Comparatively, 22.6% of Orgenesis shares are owned by institutional investors. 15.6% of Vincerx Pharma shares are owned by company insiders. Comparatively, 1.9% of Orgenesis shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Vincerx Pharma has a net margin of 0.00% compared to Orgenesis' net margin of -3,827.81%. Orgenesis' return on equity of 0.00% beat Vincerx Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vincerx Pharma	N/A	-248.33%	-132.73%
Orgenesis	-3,827.81%	N/A	-130.18%

Vincerx Pharma has higher earnings, but lower revenue than Orgenesis. Orgenesis is trading at a lower price-to-earnings ratio than Vincerx Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vincerx Pharma	N/A	N/A	-$40.16M	-$5.31	N/A
Orgenesis	$662K	0.86	-$55.36M	-$11.51	N/A

Vincerx Pharma has a beta of 1.45, suggesting that its stock price is 45% more volatile than the broader market. Comparatively, Orgenesis has a beta of 3.14, suggesting that its stock price is 214% more volatile than the broader market.

In the previous week, Vincerx Pharma had 1 more articles in the media than Orgenesis. MarketBeat recorded 1 mentions for Vincerx Pharma and 0 mentions for Orgenesis. Vincerx Pharma's average media sentiment score of 0.00 equaled Orgenesis'average media sentiment score.

Company	Overall Sentiment
Vincerx Pharma	Neutral
Orgenesis	Neutral

Summary

Vincerx Pharma beats Orgenesis on 7 of the 11 factors compared between the two stocks.

Get Vincerx Pharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VINC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VINC vs. The Competition

Export

Metric	Vincerx Pharma	Pharmaceutical Industry	Medical Sector	NASDAQ Exchange
Market Cap	$66K	$946.57M	$7.01B	$12.68B
Dividend Yield	N/A	4.84%	2.67%	9.42%
P/E Ratio	0.00	1.52	26.88	23.95
Price / Sales	N/A	110.62	574.12	115.11
Price / Cash	N/A	20.06	50.60	60.45
Price / Book	0.00	8.60	10.56	6.16
Net Income	-$40.16M	-$3.23M	$3.60B	$331.73M
7 Day Performance	N/A	-1.31%	-1.35%	-0.92%
1 Month Performance	N/A	-4.37%	-0.30%	-2.23%
1 Year Performance	N/A	27.53%	18.98%	14.79%

Vincerx Pharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VINC Vincerx Pharma	N/A	$0.01 -15.9%	N/A	-77.7%	$66K	N/A	N/A	60	News Coverage Gap Down
CARM Carisma Therapeutics	1.8869 of 5 stars	$0.01 +9.6%	$1.00 +17,443.9%	-98.8%	$239K	$10.77M	0.01	20	Gap Up
AMPE Ampio Pharmaceuticals	N/A	$0.18 flat	N/A	N/A	$208K	N/A	N/A	20
MEHA Functional Brands	0.6125 of 5 stars	$0.00 -6.0%	N/A	N/A	$201K	$6.67M	N/A	33
PTPI Petros Pharmaceuticals	N/A	$0.00 +9.5%	N/A	-85.3%	$143K	$5.11M	N/A	20

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:VINC) was last updated on 7/23/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Vincerx Pharma (VINC) Competitors

VINC vs. CARM, AMPE, MEHA, PTPI, and ORGS

How does Vincerx Pharma compare to Carisma Therapeutics?

Summary

How does Vincerx Pharma compare to Ampio Pharmaceuticals?

Summary

How does Vincerx Pharma compare to Functional Brands?

Summary

How does Vincerx Pharma compare to Petros Pharmaceuticals?

Summary

How does Vincerx Pharma compare to Orgenesis?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VINC vs. The Competition

Vincerx Pharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Vincerx Pharma (VINC) Competitors

VINC vs. CARM, AMPE, MEHA, PTPI, and ORGS

How does Vincerx Pharma compare to Carisma Therapeutics?

Does the media prefer CARM or VINC?

Do analysts prefer CARM or VINC?

Is CARM or VINC more profitable?

Do institutionals and insiders have more ownership in CARM or VINC?

Which has more risk and volatility, CARM or VINC?

Which has preferable earnings and valuation, CARM or VINC?

Summary

How does Vincerx Pharma compare to Ampio Pharmaceuticals?

Which has more volatility and risk, AMPE or VINC?

Which has preferable earnings & valuation, AMPE or VINC?

Do insiders and institutionals hold more shares of AMPE or VINC?

Does the media favor AMPE or VINC?

Is AMPE or VINC more profitable?

Summary

How does Vincerx Pharma compare to Functional Brands?

Does the media prefer VINC or MEHA?

Do analysts prefer VINC or MEHA?

Which has preferable valuation & earnings, VINC or MEHA?

Is VINC or MEHA more profitable?

Do institutionals & insiders hold more shares of VINC or MEHA?

Summary

How does Vincerx Pharma compare to Petros Pharmaceuticals?

Which has stronger valuation & earnings, VINC or PTPI?

Does the media favor VINC or PTPI?

Do institutionals and insiders hold more shares of VINC or PTPI?

Is VINC or PTPI more profitable?

Which has more risk & volatility, VINC or PTPI?

Summary

How does Vincerx Pharma compare to Orgenesis?

Do institutionals and insiders have more ownership in VINC or ORGS?

Is VINC or ORGS more profitable?

Which has better valuation and earnings, VINC or ORGS?

Which has more risk & volatility, VINC or ORGS?

Does the media prefer VINC or ORGS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VINC vs. The Competition

Vincerx Pharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools